BR112018012647A2 - composto, método para tratamento de um hospedeiro, e, uso de um composto. - Google Patents

composto, método para tratamento de um hospedeiro, e, uso de um composto.

Info

Publication number
BR112018012647A2
BR112018012647A2 BR112018012647A BR112018012647A BR112018012647A2 BR 112018012647 A2 BR112018012647 A2 BR 112018012647A2 BR 112018012647 A BR112018012647 A BR 112018012647A BR 112018012647 A BR112018012647 A BR 112018012647A BR 112018012647 A2 BR112018012647 A2 BR 112018012647A2
Authority
BR
Brazil
Prior art keywords
compound
host
treating
human
advantageous
Prior art date
Application number
BR112018012647A
Other languages
English (en)
Inventor
Efrem Pelish Henry
D Shair Matthew
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112018012647A2 publication Critical patent/BR112018012647A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de cortistatina específicos com propriedades vantajosas para administração in vivo a um hospedeiro, incluindo um humano, em necessidade do mesmo são providos. essas novas espécies têm farmacocinética vantajosa, baixa toxidade, atividade em herg baixa a moderada, e/ou outras propriedades farmacológicas que as fazem se destacar dentre a classe de cortistatinas como candidatas superiores para administração humana.
BR112018012647A 2015-12-23 2016-12-21 composto, método para tratamento de um hospedeiro, e, uso de um composto. BR112018012647A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387246P 2015-12-23 2015-12-23
US201662297494P 2016-02-19 2016-02-19
PCT/US2016/068125 WO2017112815A1 (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Publications (1)

Publication Number Publication Date
BR112018012647A2 true BR112018012647A2 (pt) 2018-12-04

Family

ID=59091204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012647A BR112018012647A2 (pt) 2015-12-23 2016-12-21 composto, método para tratamento de um hospedeiro, e, uso de um composto.

Country Status (17)

Country Link
US (1) US20180298024A1 (pt)
EP (1) EP3394072A4 (pt)
JP (1) JP2019508368A (pt)
KR (1) KR20180095051A (pt)
CN (1) CN108699085A (pt)
AU (1) AU2016377678A1 (pt)
BR (1) BR112018012647A2 (pt)
CA (1) CA3009324A1 (pt)
CL (1) CL2018001733A1 (pt)
CO (1) CO2018007535A2 (pt)
EA (1) EA201891511A1 (pt)
IL (1) IL260123A (pt)
MX (1) MX2018007804A (pt)
PH (1) PH12018501351A1 (pt)
RU (1) RU2018126984A (pt)
SG (1) SG11201805092WA (pt)
WO (1) WO2017112815A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53835A (fr) 2015-07-02 2021-08-11 Hoffmann La Roche Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN112074519A (zh) 2018-04-20 2020-12-11 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
CN113226306A (zh) * 2018-11-01 2021-08-06 希洛斯医药品股份有限公司 使用周期蛋白依赖性激酶7(cdk7)的非共价抑制剂治疗生物标志物鉴定的患者中的癌症的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283159B1 (en) * 2008-05-05 2013-10-09 The Scripps Research Institute Synthesis of (+) cortistatin a and related compounds
EP2334686B1 (en) * 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
US20130217014A1 (en) * 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) * 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
EP3505521A1 (en) * 2013-12-24 2019-07-03 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof

Also Published As

Publication number Publication date
RU2018126984A (ru) 2020-01-23
SG11201805092WA (en) 2018-07-30
WO2017112815A1 (en) 2017-06-29
MX2018007804A (es) 2019-07-04
AU2016377678A1 (en) 2018-07-12
CN108699085A (zh) 2018-10-23
CL2018001733A1 (es) 2018-11-09
CO2018007535A2 (es) 2018-07-31
PH12018501351A1 (en) 2019-02-27
IL260123A (en) 2018-07-31
CA3009324A1 (en) 2017-06-29
EP3394072A4 (en) 2019-05-29
EP3394072A1 (en) 2018-10-31
KR20180095051A (ko) 2018-08-24
US20180298024A1 (en) 2018-10-18
JP2019508368A (ja) 2019-03-28
EA201891511A1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
BR112018012647A2 (pt) composto, método para tratamento de um hospedeiro, e, uso de um composto.
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
BR112016015105A2 (pt) Conjugados var2csa-droga
CO2017011851A2 (es) Compuestos novedosos
CL2015002542A1 (es) 4-amino-6-(heterocíclico) picolinatos y 6-amino-2-(heterocíclico)pirimidin-4-carboxilatos y su uso como herbicidas.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2016001895A1 (es) Compuestos
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
UY35500A (es) Indazoles sustituidos con heteroarilo
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
CO2017011996A2 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
BR112016023607A2 (pt) uso médico de compostos de artemisinina e agonistas de gefirina
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112016009757A8 (pt) “inibidores do vírus sincicial respiratório com base em quinazolina”
UY37193A (es) Nuevos compuestos antivíricos
ECSP18023253A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2018003417A1 (es) Nuevos compuestos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]